MX2022003010A - Tratamiento de la emr mediante cambio de terapia. - Google Patents

Tratamiento de la emr mediante cambio de terapia.

Info

Publication number
MX2022003010A
MX2022003010A MX2022003010A MX2022003010A MX2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A
Authority
MX
Mexico
Prior art keywords
treatment
therapy
emr
change
ofatumumab
Prior art date
Application number
MX2022003010A
Other languages
English (en)
Spanish (es)
Inventor
Krishnan Ramanathan
Dieter Adrian Haering
Morten Bagger
Martin Merschhemke
Marina Ziehn
Ratnakar Pingili
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72709332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022003010(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2022003010A publication Critical patent/MX2022003010A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022003010A 2019-09-11 2020-09-10 Tratamiento de la emr mediante cambio de terapia. MX2022003010A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19196789 2019-09-11
EP20154736 2020-01-30
PCT/EP2020/075332 WO2021048280A1 (en) 2019-09-11 2020-09-10 Treatment of rms by switching therapy

Publications (1)

Publication Number Publication Date
MX2022003010A true MX2022003010A (es) 2022-06-02

Family

ID=72709332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003010A MX2022003010A (es) 2019-09-11 2020-09-10 Tratamiento de la emr mediante cambio de terapia.

Country Status (15)

Country Link
US (1) US20220298253A1 (cg-RX-API-DMAC7.html)
EP (2) EP3864053B1 (cg-RX-API-DMAC7.html)
JP (2) JP7794735B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220062025A (cg-RX-API-DMAC7.html)
CN (3) CN118436777A (cg-RX-API-DMAC7.html)
AU (1) AU2020344154A1 (cg-RX-API-DMAC7.html)
CA (1) CA3150947A1 (cg-RX-API-DMAC7.html)
DK (1) DK3864053T3 (cg-RX-API-DMAC7.html)
ES (1) ES2957112T3 (cg-RX-API-DMAC7.html)
FI (1) FI3864053T3 (cg-RX-API-DMAC7.html)
IL (1) IL290619A (cg-RX-API-DMAC7.html)
LT (1) LT3864053T (cg-RX-API-DMAC7.html)
MX (1) MX2022003010A (cg-RX-API-DMAC7.html)
SI (1) SI3864053T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021048280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4252847A3 (en) 2016-08-15 2023-11-15 Novartis AG Regimens and methods of treating multiple sclerosis using ofatumumab
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
WO2021204994A1 (en) * 2020-04-09 2021-10-14 Novartis Ag Ofatumumab for treating ms while maintaining serum igg
CA3215371A1 (en) * 2021-04-13 2022-10-20 Shibeshih Mitiku BELACHEW Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome
CN117529336A (zh) * 2021-04-14 2024-02-06 诺华股份有限公司 用于治疗亚洲患者的多发性硬化症的奥法木单抗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
HK1231413A1 (zh) * 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
EP4252847A3 (en) * 2016-08-15 2023-11-15 Novartis AG Regimens and methods of treating multiple sclerosis using ofatumumab

Also Published As

Publication number Publication date
AU2020344154A1 (en) 2022-04-07
EP4230655A2 (en) 2023-08-23
CN114401742A (zh) 2022-04-26
CN118403156A (zh) 2024-07-30
EP3864053B1 (en) 2023-07-05
DK3864053T3 (da) 2023-09-11
JP2026016387A (ja) 2026-02-03
LT3864053T (lt) 2023-09-11
CN114401742B (zh) 2024-05-24
SI3864053T1 (sl) 2023-12-29
CN118436777A (zh) 2024-08-06
US20220298253A1 (en) 2022-09-22
IL290619A (en) 2022-04-01
CA3150947A1 (en) 2021-03-18
KR20220062025A (ko) 2022-05-13
EP4230655A3 (en) 2023-11-01
JP7794735B2 (ja) 2026-01-06
FI3864053T3 (fi) 2023-09-13
EP3864053A1 (en) 2021-08-18
WO2021048280A1 (en) 2021-03-18
JP2022548575A (ja) 2022-11-21
ES2957112T3 (es) 2024-01-11

Similar Documents

Publication Publication Date Title
BR112022000231A2 (pt) Novos métodos
MX2021002322A (es) Nuevos metodos.
DOP2019000241A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
MX2021013974A (es) Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
AR101740A1 (es) Terapia de combinación y composiciones
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX2019005594A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
JOP20210050A1 (ar) معدلات تعبير pnpla3
AR065589A1 (es) Prediccion de respuesta a un inhibidor her
EP4327866A3 (en) Mirikizumab in the treatment of ulcerative colitis
EA201591687A1 (ru) Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
CL2022000214A1 (es) Inhibidores de enzimas
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2025013942A (es) Anticuerpos contra mucina 16 y metodos de uso de los mismos
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
BR112017022653A2 (pt) ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph?
EP4230655A3 (en) Treatment of rms by switching therapy
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2021002761A (es) Metodos para tratar la pancreatitis.
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina